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Abstract
Microglial activation has been implicated in many astrogliosis-related pathological conditions
including astroglioma; however, the detailed mechanism is not clear. In this study, we used primary
enriched microglia and astrocytes cultures to determine the role of microglial prostaglandin E2
(PGE2) in the proliferation of astrocytes. The proliferation of astrocytes was measured by BrdU
incorporation. The level of PGE2 was measured by ELISA method. Pharmacological inhibition or
genetic ablation of COX-2 in microglia were also applied in this study. We found that proliferation
of astrocytes increased following lipopolysaccharide (LPS) treatment in the presence of microglia.
Furthermore, increased proliferation of astrocytes was observed in the presence of conditioned media
from LPS-treated microglia. The potential involvement of microglial PGE2 in enhanced astrocyte
proliferation was suggested by the findings that PGE2 production and COX-2 expression in microglia
were increased by LPS treatment. In addition, activated microglia-induced increases in astrocyte
proliferation were blocked by the PGE2 antagonist AH6809, COX-2 selective inhibitor DuP-697 or
by genetic knockout of microglial COX-2. These findings were further supported by the finding that
addition of PGE2 to the media significantly induced astrocyte proliferation. These results indicate
that microglial PGE2 plays an important role in astrocyte proliferation, identifying PGE2 as a key
neuroinflammatory molecule that triggers the pathological response related to uncontrollable
astrocyte proliferation. These findings are important in elucidating the role of activated microglia
and PGE2 in astrocyte proliferation and in suggesting a potential avenue in the use of anti-
inflammatory agents for the therapy of astroglioma.
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Reactive astrogliosis is a phenomenon characterized by increased astroglial proliferation,
cellular hypertrophy and elongation of astrocytic processes. These factors can be detected using
the typical astroglial marker, glial fibrillary acidic protein (GFAP) (Neary et al., 1996; Ridet
et al., 1997). Signs of reactive astrogliosis are detected in mammalian brains following various
types of traumatic or hypoxic insults, as well as in chronic demyelination and
neurodegenerative disorders characterized by marked inflammatory responses (Oksenberg et
al., 1996; Douhou et al., 2003; Hirsch et al., 2003). Uncontrolled astrogliosis is also the main
component of most gliomas. Recently, increased attention has been focused on the cellular and
molecular mechanisms underlying astrogliosis; however, these issues are still not completely
understood. Nevertheless, recent studies indicate the potent influence of activated microglia
on astrogliosis (Penkowa et al., 2002; Rohl et al., 2007; Tilleux et al., 2007) and many
environmental toxins and other environmental pathomechanisms (pharmacologic, infectious,
and traumatic) have been implicated.
Microglia activation/proliferation and reactive astrogliosis are commonly observed and have
been considered to be a closely related pathological process during neuropathological changes
of the central nervous system (CNS). In general, activation of microglia precedes or
accompanies astrogliosis (Iravani et al., 2005; Herber et al., 2006). Several in vivo studies
report that reduction of microglial activation is associated with the reduction of astrogliosis
(Cernak et al., 2005; Gunther et al., 2005; Miller and McAllister, 2007), therefore, it has been
proposed that microgliosis may be involved in the onset and maintenance of astrogliosis
(Balasingam and Yong, 1996; Haga et al., 2002). This hypothesis was further supported by
the fact that microglia are the major sources in the brain producing pro-inflammatory factors,
which in turn could act as triggers and modulators of astrogliosis.
The purpose of this study was to determine the mechanism underlying the regulation of
astrocyte proliferation by microglia. Here, we report that presence of activated microglia is
essential in eliciting astrocyte proliferation. Increased Cyclooxygenase (COX-2) expression in
activated microglia and the subsequent enhancement of PGE2 released from activated
microglia were found to be associated with enhanced astrocyte proliferation in vitro.
Materials and Methods
Reagents
Lipopolysaccharide (LPS) (Escherichia coli strain O111:B4) was purchased from Calbiochem
(La Jolla, CA). 96 insert-well plates and 6 insert-well plates were purchased from Millipore
Company (Bedford, MA). Polyclonal antibody against COX-2 was purchased from Caymen
(Ann Arbor, MI). Rabbit anti-GAPDH was obtained from Abcam (Cambridge, MA). The
Vectastain avidin-biotin complex (ABC) kit and biotinylated secondary antibodies were
purchased from Vector Laboratories (Burlingame, CA). Tissue culture media, supplements,
fetal bovine serum and horse serum were obtained from Invitrogen (San Diego, CA). The
endotoxin level in the serum is less than 0.3 unit/ml. Dup-697 and AH6809 were purchased
from Cayman Chemical Company (Ann Arbor, MI).
Animals
Timed-pregnant Fisher F344 rats were obtained from Charles River Laboratories (Raleigh,
NC). Rat cultures were used in Figure 1–4. Timed-pregnant C57BL/6J mice were purchased
from Jackson Laboratory (Bar Harbor, ME). The COX-2−/− mice on a C57BL/6-129Ola
background have been maintained by heterozygous × heterozygous for more than 50
generations (Langenbach et al., 1999). The COX-2−/− mice used in the present study were
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produced by breeding COX-2+/− male and female mice so that COX-2+/+, COX-2+/− and
COX-2−/− pups were produced in each litter. Mouse cultures were used in Figure 5. The
breeding of the mice was carried out to achieve timed pregnancy with an accuracy of ±0.5 days.
Animals were treated humanely and with regard for alleviating suffering. Housing and breeding
of animals were done in accordance with National Institutes of Health guidelines (Office of
Laboratory Animal Welfare 2002). Animals were maintained on a 12:12 h light: dark cycle
and fed ad libitum. Housing and breeding of the animals were performed in accordance with
the National Institutes of Health Guidelines strictly.
Cell culture
Primary microglia-enriched cultures and astrocyte-enriched cultures were prepared from the
whole brains of 1 or 2-day-old mice, as described previously (Liu et al., 2003). Briefly, brain
tissues, devoid of meninges and blood vessels, were dissociated by a mild mechanical
trituration. The isolated cells (5 × 107) were seeded in 150 cm2 culture flasks in DMEM/F12
containing 10% fetal bovine serum, 2 mM L-glutamine, 1 mM sodium pyruvate, 100 μM
nonessential amino acids, 50 U/ml penicillin and 50 μg/ml streptomycin. The cultures were
maintained at 37°C in a humidified atmosphere of 5% CO2 and 95% air. The complete medium
was changed 4 d later. When reaching confluence (12–14 d), microglia were separated from
astrocytes by shaking the flasks at 180 rpm for 5 h. The astrocytes were maintained for one to
two more weeks; during the time 0.1 mM L-leucine methyl ester was added to avoid the residue
microglia. Astrocytes were then collected with trypsin/EDTA solution. After determination
the concentration, astrocytes at 1 × 104/well were seeded to 96-well plates. The purity of the
microglia-enriched cultures was >98% and the contamination of microglia in the astrocyte-
enriched culture was less than 0.1% as determined by immunocytochemical staining (Iba-1
and GFAP were used as staining marker for microglia and astrocyte, respectively).
Transwell coculture
Astrocytes at 1 × 104/well were seeded to 96-well plates and microglia at 3 × 103/well were
plated onto the top side of the transwell inserts. The astrocytes and microglial cells share the
same medium but no direct cell–cell interactions are possible due to the physical separation of
the cells by a polycarbonate membrane. The pore size of the transwell (0.4 μm) allows no cell
migration through the membrane. At the time of seeding, microglia were 2 weeks old and
astrocytes were 3–4 weeks old. Viability of the astrocytes on the 96-well plate and microglia
on the transwells prior to treatment was verified using trypan blue staining.
Cell proliferation assay
Cell proliferation was detected with a cell proliferation ELISA kit from Roche (Indianapolis,
IN), based on the measurement of BrdU incorporation during DNA synthesis. Assays were
performed according to the protocol provided by the manufacturer. Briefly, primary enriched
astrocyte cultures were treated with 5–20 ng/ml of LPS (15–60 EU/ml) in 96-well plates in a
final volume of 100 μl/well for 72 h. This concentration range of LPS has been routinely used
in our laboratory to generate moderate level of inflammatory response in microglia.
Additionally, the PGE2 level stimulated by 5–20 ng/ml LPS was comparable to the PGE2 level
detected in the brain (Loh et al., 2002; Yang et al., 2008; Zhang et al., 2008). The inhibitors
used in the present study were applied to the cell culture 1 h prior to LPS challenge and the
incubation lasted for 72 h. Subsequently, 10 μl/well BrdU was added to the cells (final
concentration: 10 μM) and the cells were reincubated for 4 h. During this labeling period, the
pyrimidine analogue BrdU was incorporated in place of thymidine into the DNA of
proliferating cells. After removing the culture medium, cells were fixed and the DNA was
denatured by adding 200 μl/well FixDenat to the cells and incubation for 30 min at room
temperature. After removing the FixDenat solution, a 100 μl/well anti-BrdU-POD working
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solution was added for another 90 min at 15–25°C. The antibody conjugate was removed by
flicking off and rinsing wells three times with 300 μl/well washing solution. Cells were then
incubated with 100 μl/well substrate solutions for 15 min. The absorbance at 370 nm was read
with a SpectraMax Plus microplate spectrophotometer (Molecular Devices, Sunnyvale, CA).
The developed color, and thereby the absorbance values, directly correlates with the amount
of DNA synthesis and thus with the number of proliferating cells in the respective
microcultures.
PGE2 production assay
Cultures were treated with LPS at given doses. After 72 h, supernatants were collected and
PGE2 concentration in the supernatant was determined using a PGE2 Enzyme Immunometric
Assay (EIA) kit from Cayman, according to the manufacturer’s instructions.
Protein extraction and Western blot analysis
Astrocyte-enriched cultures and microglia-enriched cultures treated with 20 ng/ml LPS for 72
h were detached by scraping in sample buffer (pH 7.9) containing 10 mM HEPES, 1.5 mM
MgCl2, 10 mM KCl, 1.5 mM phenylmethylsulfonyl fluoride, and 0.5 mM dithiothreitol.
Isolated proteins were adjusted to equal concentrations and amounts. The loaded protein
amount for microglia is 20 μg, for astrocyte is 60 μg. Proteins were separated using 4 to 12%
Bis-Tris ν-polyacrylamide gel electrophoresis gel and then transferred to polyvinylidene
difluoride membranes (Novex, San Diego, CA). Membranes were blocked with 5% nonfat
milk and incubated with rabbit anti-COX-2 antibody (1: 2000) or rabbit anti-GAPDH (1:2000)
overnight at 4°C. Membranes were placed in horseradish peroxidase-linked anti-rabbit IgG
(1:3000) for 1 h at 25°C and ECL+Plus reagents (GE Healthcare, Little Chalfont,
Buckinghamshire, UK) were used as a detection system. Densitometric analysis for each
sample was performed (ImageMaster RVDS; GE Healthcare) using three measurements on
three separate bolts.
Real-time RT-PCR analysis
Expression levels of selected genes were quantified using real-time RT-PCR analysis. Briefly,
total RNA was reverse transcribed using MuLV reverse transcriptase and oligo-dT primers.
The forward and reverse primers for select and the sequences were designed using the ABI
Primer Express software (Foster City, CA) as follows. COX-2, Forward:
GCTGGCCTGGTACTCAGTAGGTT; Reverse: CGAGGCCACTGATACCTATTGC.
GAPDH, Forward: CCTGGAGAAACCTGCCAAGTAT; Reverse:
AGCCCAGGATGCCCTTTAGT. SYBR green PCR master mix (Applied Biosystems,
Cheshire, UK) was used for real-time PCR analysis. Cycle time values of the genes were first
normalized with GAPDH of the same sample, and then the relative differences between control
and treatment groups were calculated and expressed as relative increases, setting the control
as 100%.
Statistical Analysis
Data are expressed as mean ± S.E.M. The level of significance was set of p < 0.05 in both
ANOVA and post-hoc Bonferroni’s t-test statistics using the StatView program (Abacus
Concepts, Berkeley, CA). A value of p < 0.05 was considered statistically significant.
Results
Microglia enhance LPS-induced astrocyte proliferation
In order to study the role of microglia in astrocyte activation, LPS, a widely used endotoxin,
was used to stimulate the activation of microglia and induce astrocyte proliferation. Primary
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enriched astrocyte cultures with or without microglia in the insert wells of a transwell culture
apparatus were treated with different concentrations of LPS (5, 10, 20 ng/ml) in a final volume
of 200 μl/well for 72 h. Cell proliferation was then detected using a BrdU incorporation kit.
As shown in Fig. 1A, BrdU incorporation was greatly potentiated to roughly 140%, 200% and
250% in astrocyte-microglia co-cultures following 5, 10, 20 ng/ml LPS, respectively. LPS
treatment also increased BrdU incorporation in primary enriched astrocyte cultures but to a
much less extent (30 to 50%). These results indicated that the existence of activated microglia
contributed to astrocyte proliferation. Since there were no direct cell-cell contacts between
microglia and astrocytes in this experiment, it is likely that pro-inflammatory factors released
by activated microglia are involved in the astrocyte responses. To confirm this speculation,
primary enriched microglial cultures were treated with equal concentrations of LPS for 72 h,
and the conditioned media was collected without being concentrated and added to primary
enriched astrocyte cultures as 100%. Incubation with conditioned media lasted for 72 h and
then BrdU incorporation was measured to evaluate astrocyte proliferation. As showed in Fig.
1B, conditioned media from activated microglia induced significant astrocyte proliferation in
a LPS dose-dependent manner. These results further suggest that the pro-inflammatory factors
released by activated microglia are associated with astrocyte proliferation.
LPS treatment induced COX-2 gene and protein expression in primary enriched microglial
and astrocyte cultures
To determine whether prostaglandins are involved in microglia-astrocyte communication, the
expression of COX-2, an inducible enzyme expressed in inflamed tissues and its product
PGE2 in both microglia and astrocytes were measured. Enriched microglial and astrocyte
cultures were treated with the same range of concentrations of LPS (5–20 ng/ml). COX-2 gene
expression was measured using RT-PCR at 6 h after LPS treatment and COX-2 protein
expression was measured by immunoblotting 24 h following of LPS treatment. As shown in
Fig. 2A, the basal expression of COX-2 gene was low in non-treated microglial and astrocytes
cultures. LPS treatment significantly enhanced the expression level of microglial COX-2 gene
in a dose-dependent manner. In contrast, the levels of COX-2 mRNA in astrocytes were more
subdued compared to microglia. Consistent with the gene expression change, similar changes
were observed in the levels of COX-2 protein after LPS treatment (Fig. 2B and 2C).
PGE2 is involved in LPS-induced astrocyte proliferation
We then measured the ability of microglia and astrocytes to produce PGE2 after LPS treatment.
Primary enriched microglial and astrocyte cultures were treated with various LPS
concentrations. Supernatants were collected 72 h after treatment and levels of PGE2 were
determined by ELISA. As shown in Fig. 3A, LPS treatment significantly induced PGE2
production from enriched microglial cultures in a dose-dependent manner. When treated with
20 ng/ml LPS, PGE2 levels produced by activated microglia were roughly 20 times higher than
that produced by activated astrocytes. This observation indicates that microglia are a major
source of PGE2 production.
To ascertain that PGE2 released by activated microglia plays a role in mediating astrocyte
proliferation, exogenous PGE2 in the concentration range produced by microglia after LPS
treatment (Fig. 3A) was added to enriched astrocytes culture and incubated for 72 h. As shown
in Fig. 3B, PGE2 significantly increased the incorporation of BrdU in astrocytes in a dose-
dependent fashion.
To further confirm the essential role of microglial PGE2 in mediating astrocyte proliferation,
we pretreated microglia-astrocyte co-cultures with a non-selective PGE2 receptor antagonist
AH6809 for 1 h and then challenged the cells with 20 ng/ml LPS. As shown in Fig 3C, AH6809
significantly inhibited LPS induced astrocyte proliferation in a dose-dependent manner.
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However, AH6809 at high concentrations failed to abolish astrocyte proliferation. Although
this might because of the failure to block all the receptors of PGE2 by AH6809, it is likely that
pro-inflammatory factors other than PGE2, released by activated microglia also contribute to
the enhanced astrocyte proliferation.
COX-2 specific inhibitor DuP697 attenuated LPS-induced PGE2 production and astrocyte
proliferation
The effect of microglial PGE2 in astrocyte proliferation was further confirmed using a COX-2
specific inhibitor DuP697. Similar to Fig 1, transwell astrocyte-microglia co-cultures were
used for this experiment. Different concentrations of COX-2 specific inhibitor DuP697 were
applied 1 h prior to LPS treatment. Dup-697 effectively inhibited the PGE2 level in the medium
(Fig. 4A). The same pretreatment also significantly attenuated LPS-induced BrdU
incorporation in enriched astrocyte cultures in a dose-dependent manner (Fig. 4B). However,
high concentrations of DuP697 failed to abolish the astrocyte proliferation induced by LPS.
Thus, these two independent experiments both indicated that pro-inflammatory factors other
than PGE2 released by activated microglia participated in the LPS-induced increase of astrocyte
proliferation.
Microglia from COX-2−/− mice showed impaired effect in mediating astrocyte activation
To further confirm that microglial PGE2 is involved in mediating astrocyte proliferation,
primary enriched microglia prepared from COX-2+/+ and COX-2−/− mice were seeded in insert
wells, then loaded on top of enriched COX-2+/+ astrocyte cultures pre-seeded in 96 wells.
Cultures were then treated with different concentrations of LPS for 72 h and astrocyte
proliferation was determined. As shown in Fig. 5A, LPS treatment significantly increased BrdU
incorporation in astrocyte cultures when microglia from COX-2+/+ mice were present in the
insert wells. In contrast, BrdU incorporation in astrocytes was much lower when microglia
from COX-2−/− mice were used. This result was consistent with the finding that LPS-induced
increase levels of PGE2 was significantly abolished in COX-2−/− microglia cultures (Fig. 5B).
Discussion
In this study we provided strong evidence indicating that activation of microglia by LPS
promoted an increase in astrocyte proliferation. We further demonstrated that activated
microglia enhanced astrocyte proliferation through the up-regulation of COX-2 and subsequent
release of PGE2. Pharmacological inhibition or genetic ablation of COX-2 in microglia reduced
the release of PGE2 and greatly diminished its ability to promote astrocyte proliferation.
Furthermore, a PGE2 receptor antagonist, AH6809, was shown to attenuate microglia-mediated
increase in astrocyte proliferation.
Astrocytes can be activated in response to many brain injuries, such as stroke, trauma, tumor,
or neurodegenerative diseases, as well as multiple endogenous or exogenous stimuli including
fibroblast growth factor or cannabinoids released by damaged neurons (Barbeito et al., 2004;
O’Callaghan and Sriram, 2005; Pehar et al., 2005; Widmer et al., 2008). Neuronal death is
capable of inducing astrocyte proliferation even without the involvement of microglia. For
example, Aicha Douhou reported in the substantia nigra of weaver knowout mice, the onset of
dopaminergic cell loss was correlated with a large and permanent increase in the number of
astrocyte while only a transient activation of microglial cells was found (Douhou et al.,
2003). Besides neuronal death induced astrocyte proliferation, there are also numerous studies
describe intimate interaction between microglia and astrocytes. There have been several
references reporting the effect of microglia on astrocyte proliferation in vivo. It is reported that
early onset microglial activation/proliferation can significantly influence the subsequent
development of reactive astrogliosis and glial scar formation in spinal cord injury animal model
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(Tian et al., 2007). Besides, intra-gliomal density of amoeboid microglia is reported to be
higher than in normal brain and correlates with the grade of malignancy (Wierzba-Bobrowicz
et al., 1994; Graeber et al., 2002). The presence of microglia in and around gliomas reflects
the immune response or microglial recruitment by gliomas and may play a functional role in
glioma survival. It is also documented that many substances produced by microglia can
influence glioma proliferation and migration (Watters et al., 2005). Concerning the astroglial
cell number and cell trophy (GFAP expression), it’s reported that activated microglia enhance
the astrocyte growth but do not have a hypertrophic effect on astrocyte (Rohl et al., 2007).
Besids, proinflammatory cytokines like IL-1 and TNFα are reported to produce a decrease of
GFAP expression in astrocyte culture (Selmaj et al., 1991; Oh et al., 1993; Lee et al., 1995;
Murphy et al., 1995). It’s speculated that activated microglia might be to a great extent involved
in the onset of astrogliosis but other or additional cell interaction might be responsible for the
typical increase of GFAP in astrogliosis. As an important feature of astrogliosis, astrocyte
proliferation has been more and more used in evaluation the extent of astrogliosis. So, in the
present study, we use astrocyte proliferation as a parameter to evaluate the effect of activated
microglia. By using transwell cultures of purified astrocytes and microglia, we provided strong
evidence that microglia mediate LPS-induced astrocyte proliferation. In the presence of
microglia, LPS greatly enhanced the proliferation of astrocytes. In contrast, LPS-induced
increase in BrdU incorporation was minimal in enriched astrocyte cultures. These results
clearly point out the essential role of microglia in astrocyte proliferation.
We further examined the possible factors released from activated microglia which may
contribute to LPS-elicited astrocyte proliferation. LPS has been widely used as a means to
stimulate the release of inflammatory mediators from activated microglia. Among the pro-
inflammatory factors released by microglia, PGE2 plays a crucial role in various biological
events such as neuronal function, female reproduction, vascular hypertension, tumorigenesis,
kidney function and inflammation (Hori et al., 1998; Zacharieva et al., 2004; Glodny and Pauli,
2006). Two enzymes responsible for the production of PGE2 are designated as COX-1
(constitutive) and COX-2 (inducible) (Terlain et al., 1995; Griswold and Adams, 1996; Park
et al., 2006). It is generally believed that constitutive COX-1 is involved in normal
physiological processes and inducible COX-2 is primarily responsible for the production of
PGs in inflamed tissues and associated with inflammatory diseases. Accumulating evidence
indicates that increased PGE2 levels resul from COX-2 over expression are important in cell
proliferation, apoptosis and migration (Murakami and Kudo, 2004). Under pathological
conditions such as tumor, especially those associated with a glial response, increased COX-2
expression and elevated levels of PGE2 have been found in the brain (Hata and Breyer, 2004;
Takemiya et al., 2007). In the present study, the direct effect of exogenous PGE2 on astrocyte
activation and the inhibitory effect of AH6809, a non-selective PGE2 receptor inhibitor,
suggested the involvement of PGE2 in microglia-enhanced astrocyte proliferation. Further
evidence showed that although LPS treatment increased COX-2 expression and PGE2
production in both microglia and astrocytes, PGE2 produced by microglia is roughly 20 fold
more than that produced by an equal number of actrocytes. Thus, these observations
demonstrate that microglia are the major sources for PGE2 production. These results are
consistent with findings that LPS induces minimal increases in astrocyte proliferation in the
absence of microglia.
Microglia are the major sources in the brain producing pro-inflammatory factors, which in turn
could act as triggers and modulators of astrocyte proliferation. The effect of other pro-
inflammatory factors on the induction of astrocyte proliferation has been examined in several
studies. Pro-inflammatory factors such as IL-1, IL-6, PGD2 and TNFα have been shown to
induce, enhance or accompany astrocyte proliferation (Barna et al., 1990; Selmaj et al.,
1991; Balasingam et al., 1994; Herx and Yong, 2001; Cardenas and Bolin, 2003; Mohri et
al., 2006). However, the concentrations of these proinflammatory factors used in previous
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studies were 2 to 3 orders of magnitude higher than the levels detected in microglia conditioned
media or in the brain. In contrast, the concentration of PGE2 added to the cultures to promote
astrocyte proliferation in this study was in the range of that produced by LPS-activated
microglia and in the range of PGE2 levels that detected in brain (Loh et al., 2002). This is of
critical importance that inhibition of PGE2 synthesis or antagonism of PGE2 receptors might
be useful in the prevention and/or treatment of diseases related to un-controlled astrocyte
proliferation. It is worth pointing out that the PGE2 receptor inhibitor used in the present study
is reported to bind to PGD2 receptor, too (Kiriyama et al., 1997). PGD2 signal pathway is
reported to be involved in astrocyte proliferation (Mohri et al., 2006). So, the inhibitory effect
of AH6809 we showed in Figure 3C is possible part of the effect on PGD2 pathway besides
the PGE2 pathway.
The role of microglial COX-2 and PGE2 in astrocyte proliferation was further confirmed by
using a COX-2 selective inhibitor and COX-2 deficient microglia. Dup-697, a selective COX-2
inhibitor, significantly and dose-dependently inhibited LPS-induced increases in production
of PGE2 and astrocyte proliferation. Results from pharmacological manipulation were further
substantiated by using glial cultures prepared from COX-2-deficient mice. COX-2-deficient
microglial cultures produced significant less PGE2 and elicited a much lower rate of astrocyte
proliferation than microglial cultures from wild type control mice. Taken together, these
findings indicate that PGE2 is a potent mediator for microglia-induced astrocyte activation and
suggest therapeutic possibilities that either inhibition of PGE2 synthesis or treatment with
antagonists of PGE2 receptors might be useful in the prevention and/or treatment of glioma.
The findings in this study are of particular clinical significance for the mechanistic investigation
and treatment of gliomas, which develop mainly from astrocytes and are the most common
primary brain tumors and one of the leading causes of cancer-related deaths in young children
and adults (Noble and Mayer-Proschel, 1997; Shapiro, 2001). All current treatment options
have limitations. Radiation therapy may be associated with neurotoxicity in adjacent normal
tissues. Chemotherapy is constrained by the blood-brain barrier. Surgical resection is limited
by non-circumscribed borders of most gliomas. The newest generation of treatments includes
more effective cytotoxic agents, so-called targeted compounds, and biologics/
immunotherapeutics. To date, none of these has proven highly effective across the wide
spectrum of tumors. Such limitations explain the reasons why survival rates have improved so
little over the past few decades of research regarding treatment of glioma. Thus, identifying
and ultimately targeting the molecules that lead to glioma progression will have a strong impact
on future treatment strategies (Salgaller and Liau, 2006; Lukas et al., 2007).
In summary, this study supports the view that activated microglia may be critically involved
in the onset and maintenance of astrocyte proliferation. Moreover, our data provide evidence
that astrocyte activation is likely mediated in part through the up-regulation of COX-2
expression in microglia and subsequent PGE2 production. Though detailed molecular
characterization of this process awaits further investigations, the present study demonstrates
that interruption of PGE2 effect inhibits proliferative in astrocytes. In conjugation with previous
studies indicating COX-2 inhibitors are effective in the treatment of glioma (Joki et al.,
2000; Giglio and Levin, 2004; New, 2004), PGE2 might be an important potential target for
therapeutic interventions in the management of glioma.
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Figure 1. Activated microglia contribute to astrocyte proliferation
(A) Primary enriched astrocyte cultures with or without microglia within insert wells were
treated with various concentrations of LPS in a final volume of 200 μl/well for 72 h. (B) Primary
enriched microglial cultures were treated with different concentrations of LPS for 72 h, then
the conditioned media was collected and added to primary enriched astrocyte cultures.
Incubation was lasted for an additional 72 h. Cell proliferation was assayed using a BrdU
ELISA kit as described in Material and Methods. Results are mean ± S.E.M of three
experiments performed in triplicate. * p <0.05, compared with corresponding control cultures;
# p <0.05, compared with astrocytes alone after same treatment.
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Figure 2. LPS treatment induced COX-2 gene and protein expression in primary enriched
microglial and astrocyte cultures
Enriched microglial and astrocyte cultures were treated with different concentrations of LPS.
Then COX-2 gene expression was assayed using RT-PCR (A) at 6 h after treatment and COX-2
protein expression was assayed using Western blot (B) at 24 h post treatment. Quantitative
analysis of COX-2 protein expression was shown in C. Data have been normalized to GAPDH
and are mean ± S.E.M of three experiments performed in triplicate. * p <0.05, compared with
corresponding control cultures; # p <0.05, compared with astrocytes after same treatment.
Zhang et al. Page 13













Figure 3. PGE2 is involved in astrocyte proliferation
(A) Primary enriched astrocyte and microglial cultures were treated with LPS at given doses.
The supernatant were collected 72 h after treatment and PGE2 concentrations were assayed
using an ELA kit as described in Material and Methods. * p <0.05, compared with
corresponding control cultures; # p <0.05, compared with astrocytes after same treatment. (B)
Different concentrations of PGE2 were added to purified astrocyte cultures and the incubated
for 72 h. Cell proliferation was assayed using a BrdU ELISA kit. * p <0.05, compared to
corresponding control cultures. (C) Astrocytes and microglia co-cultures in transwell were pre-
treated with the non-selective PGE2 receptor antagonist AH6809 for 1 h then challenged with
20 ng/ml LPS for 72 h. Astrocyte proliferation was then measured. Results are mean ± S.E.M
of three experiments performed in triplicate. * p <0.05, compared with control cultures; # p
<0.05, compared with LPS treatment group.
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Figure 4. COX-2 specific inhibitor DuP697 attenuated LPS-induced astrocyte proliferation
COX-2 specific inhibitor DuP697 was applied 1 h prior to LPS treatment in primary enriched
astrocyte cultures together with insert wells with microglia. (A) The supernatant were collected
72 h after treatment and PGE2 concentration was assayed using an EIA kit. (B) Cell
proliferation was assayed at 72 h after treatment using a BrdU ELISA kit. Results are mean ±
S.E.M of three experiments performed in triplicate. * p <0.05, compared with control cultures;
# p <0.05, compared with LPS treatment group.
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Figure 5. Microglia from COX-2−/− mice showed impaired effect in mediating astrocyte activation
Primary enriched astrocyte cultures from COX-2+/+ mice along with insert wells with microglia
from COX-2+/+ and COX-2−/− mice were treated with different concentrations of LPS for 72
h. (A) Cell proliferation was assayed using a BrdU ELISA kit. (B) The supernatant were
collected 72 h after treatment and PGE2 concentration was assayed using an EIA kit. Results
are mean ± S.E.M of three experiments performed in triplicate. * p <0.05, compared with
corresponding control cultures; # p <0.05, compared with insert wells plus COX-2+/+
microglial cultures.
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